4 Overstated
Positive TSPO scans showing microglial activation are observed in Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, major depressive disorder, PTSD, and long COVID.
"we see that the TSPO scan is positive, as you would expect, in Alzheimer's, in Parkinson's, in multiple system atrophy, progressive supranuclear palsy, major depressive disorder, post-traumatic stress, and even long COVID." (said at 0:05:09)
While translocator protein (TSPO) PET imaging reliably shows increased radiotracer uptake (reflecting glial activation/neuroinflammation) in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), as well as in corticolimbic circuits in major depressive disorder, the claim is overstated for PTSD and long COVID. In long COVID, case-control TSPO PET studies have found that TSPO availability is not significantly elevated compared to healthy controls. In PTSD, in vivo TSPO PET imaging studies frequently report decreased TSPO binding (neuroimmune suppression) rather than increased TSPO signals.
- supports: Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron E… (Movement disorders : official journal of the Movement Disorder Society 2022) · cited 42x in the literature
"We found a pattern of significantly increased regional glial TSPO binding in patients with MSA. Intriguingly, our data are in line with severe neuroinflammation in MSA." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis… (Brain, behavior, and immunity 2023) · cited 73x in the literature
"Across all the illness categories, we observed a significantly higher TSPO PET signal in cases compared to controls for the cGM (n = 121 studies, SMD = 0.358, P FDR < 0.001, I 2 = 68%), with a significant difference between the illness categories (P = 0.004). cGM increases were only significant for Alzheimer's disease (SMD = 0.693, P FDR < 0.001, I 2 = 64%) and other neurodegenerative disorders (SMD = 0.929, P FDR < 0.001, I 2 = 73%). Cortico-limbic increases (n = 97 studies, SMD = 0.541, P < 0.001, I 2 = 67%) were most prominent for Alzheimer's disease, mild cognitive impairment, other neurodegenerative disorders, mood disorders and multiple sclerosis." (abstract, results)
pubmedfull study (doi) - supports: Inflammation PET and plasma neurofilament light predict survival in people with progressiv… (Brain communications 2025) · cited 3x in the literature
"In the PET cohort, higher levels of localized inflammation in subcortical regions [rho = -0.49, P = 0.02, Bayes factor (BF) = 8.07] and plasma NfL (rho = -0.57, P = 0.01, BF = 4.63) were associated with shorter survival, while PSPRS scores were not significant predictors of survival." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activatio… (Journal of neurology 2026)
"LC TSPO availability did not differ from HCs in any studied brain area. However, lower WM TSPO availability in individuals with longer LC duration suggests COVID-19-associated neuroinflammation may subside with time, while the association between limbic TSPO availability and LC severity may imply a role for limbic activity in LC symptomology." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Having type 2 diabetes increases the risk of developing Parkinson's disease by 85%.
"If you have type 2 diabetes, your risk of Parkinson's is increased by 85%." (said at 0:12:24)
Type 2 diabetes is associated with an increased risk of Parkinson's disease, but large meta-analyses show the relative risk increase is substantially lower than 85%. Comprehensive meta-analyses of prospective cohort studies consistently estimate an increased risk of roughly 15% to 37% (e.g., summary RR = 1.27, 95% CI 1.20–1.35 in a meta-analysis of 15 cohort studies encompassing nearly 30 million participants; RR = 1.22, 95% CI 1.08–1.37 in a 25-study meta-analysis). Claiming an 85% increase significantly overstates the effect size observed in the epidemiologic literature.
- contradicts: Diabetes mellitus, prediabetes and the risk of Parkinson's disease: a systematic review an… (European journal of epidemiology 2023) · cited 70x in the literature
"Fifteen cohort studies (29.9 million participants, 86,345 cases) were included in the meta-analysis. The summary RR (95% CI) of PD for persons with diabetes compared to persons without diabetes was 1.27 (1.20-1.35, I 2 = 82%)... Our results suggest that patients with diabetes have a 27% increased relative risk of developing PD compared to persons without diabetes" (abstract, results)
pubmedfull study (doi) - contradicts: The risk of Parkinson's disease in diabetic people: an updated systematic review and meta-… (Acta neurologica Belgica 2024) · cited 9x in the literature
"In the meta-analysis, 25 studies encompassing a total of 39,209,316 participants were incorporated. The collective estimation of the relative risk concerning the association between Diabetes Mellitus (DM) and Parkinson's Disease (PD) yielded a value of 1.22 (95% CI 1.08-1.37)." (abstract, results, passage verified)
pubmedfull study (doi)
Interventional trials using lifestyle modification have proven effective in improving cognitive outcomes in individuals with established Alzheimer's disease.
"interventional trials using lifestyle modification have proven effective even in individuals with established Alzheimer's disease." (said at 1:07:42)
While a 2024 randomized controlled phase 2 trial by Ornish et al. (n=51) demonstrated improvements or stabilization in cognitive and functional measures (such as CGIC, CDR-SB, and CDR-Global) following a 20-week intensive multidomain lifestyle intervention in patients with mild cognitive impairment or early dementia due to Alzheimer's disease, stating that lifestyle modification has 'proven effective' in established Alzheimer's disease overstates the evidence. The existing evidence is preliminary, derived from a small sample over a short duration, and most large multidomain lifestyle trials (e.g., FINGER) have focused on dementia prevention in at-risk older adults rather than treatment of established Alzheimer's disease.
C15 (pentadecanoic acid) strengthens cells to support healthy aging.
"active ingredient, C15, that strengthens your cells to support healthy aging. Don't take my word for it; look at the science." (said at 1:01:44)
While published in vitro and preclinical research suggests that pentadecanoic acid (C15:0) incorporates into lipid membranes, enhances membrane stability, inhibits ferroptosis, and shares cell-signaling pathways (such as AMPK activation and mTOR inhibition) with longevity-associated compounds, these findings stem primarily from cell-culture phenotyping assays, animal models, and theoretical reviews (the 'Cellular Stability Hypothesis'). Robust clinical trial evidence demonstrating that C15:0 supplementation strengthens human cells to promote healthy aging in humans is currently lacking, making the claim overstated.
- partial: Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based… (Nutrients 2023) · cited 56x in the literature
"To assess the potential for C15:0 to enhance processes associated with longevity and healthspan, we used human cell-based molecular phenotyping assays to compare C15:0 with three longevity-enhancing candidates: acarbose, metformin, and rapamycin." (abstract, results, passage verified)
pubmedfull study (doi) - partial: The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associate… (Metabolites 2024) · cited 18x in the literature
"Pentadecanoic acid (C15:0), an odd-chain saturated fat, is an essential fatty acid with the primary roles of stabilizing cell membranes and repairing mitochondrial function. By doing so, C15:0 reverses the underpinnings of ferroptosis. Under the proposed "Cellular Stability Hypothesis", evidence is provided to show that cell membranes optimally need >0.4% to 0.64% C15:0 to support long-term health and longevity." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.